[Featured Stock] Curexo, Expectations for Increasing Overseas Sales of Medical Robots Starting from India

Curexo is showing strong performance. It is interpreted that the securities firm's analysis predicting an increase in medical robot sales overseas, starting from India, has influenced this trend.

As of 2:45 PM on the 17th, Curexo was trading at 9,810 KRW, up 390 KRW (4.14%) compared to the previous trading day.

On this day, Sangsangin Securities evaluated that Curexo's exports to India are recovering and that efforts to pioneer new overseas markets are underway.

Researcher Ha Taegi of Sangsangin Securities said, "From the fourth quarter of 2024, India's Meril Healthcare reduced sales of its own products due to quality issues and resumed importing Curexo's QVius-Joint. Curexo hedged its exclusive contract with Meril Healthcare and, starting in 2025, additionally supplied to Indian companies Shelby and BioRad, transitioning to a competitive sales system." He added, "Curexo established a local corporation in India for consumables sales and after-sales service, and sales in India are expected to increase significantly from 2025."

He emphasized, "In 2024, QVius-Joint received regulatory approval in Indonesia and Malaysia, and in the first quarter of 2025, also in Taiwan. From 2025, sales will gradually occur in these countries as well."

Along with this, entry into the Japanese market is also underway. He said, "We are pursuing a supply contract with Kyocera, a leading Japanese spinal implant company," and evaluated, "Meaningful sales could occur in Japan in 2025."

He continued, "Although it is still early, under an optimistic scenario, the annual sales for 2025 can be estimated at around 80 to 90 billion KRW," and added, "By around July to August 2025, we expect to have a clearer outlook."

This content was produced with the assistance of AI translation services.